Integrated Diagnostics Holdings (LSE:IDHC) Research & Development: $0.00 Mil (TTM As of Mar. 2026)


LSE:IDHC Integrated Diagnostics Holdings PLC LSE:IDHC
58 GF Score
Price $0.50
GF Value $0.57
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Integrated Diagnostics Holdings Research & Development?

Integrated Diagnostics Holdings LSE:IDHC +0.40% 58 Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus rates LSE:IDHC with a GF Score™ of 58/100 and a GF Value™ of $0.57 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Integrated Diagnostics Holdings's Research & Development for the three months ended in Mar. 2026 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Integrated Diagnostics Holdings  (LSE:IDHC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Integrated Diagnostics Holdings Research & Development Related Terms

Integrated Diagnostics Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Integrated Diagnostics Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integrated Diagnostics Holdings Research & Development Chart

Integrated Diagnostics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Integrated Diagnostics Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LSE:IDHC
58GF Score
Integrated Diagnostics Holdings PLC LSE:IDHC
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integrated Diagnostics Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.00 Mil mean?
Integrated Diagnostics Holdings (LSE:IDHC) has a Research & Development of $0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Integrated Diagnostics Holdings and its competitors.
Is Integrated Diagnostics Holdings' Research & Development too high?
Integrated Diagnostics Holdings' current Research & Development is $0.00 Mil. Overall, Integrated Diagnostics Holdings has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' Research & Development compare to TMO and DHR?
Integrated Diagnostics Holdings' Research & Development of $0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Integrated Diagnostics Holdings and its competitors. Integrated Diagnostics Holdings's current Research & Development is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.57, compared to a current price of $0.50 — trading 11.9% below its estimated fair value. The current Research & Development is $0.00 Mil. Integrated Diagnostics Holdings' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?

Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued. The current stock price of $0.50 is trading 11.9% below its estimated GF Value™ of $0.57. GuruFocus considers Integrated Diagnostics Holdings to be Modestly Undervalued.

Key valuation signals for LSE:IDHC:

  • Research & Development: $0.00 Mil
  • GF Value™: $0.57 vs. price of $0.50 (11.9% below fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Integrated Diagnostics Holdings Business Description

Address 12 Castle Street, St Helier, JEY, JE2 3RT
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
58GF Score

Get the complete analysis for LSE:IDHC

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.50
Price
$0.57
GF Value